Diabetes complications

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes Obes MetabPublished Systematic review and network meta-analysis of randomised trials

Authors' conclusion

In patients with HFpEF, GLP-1RA, SGLT2i and MRA significantly reduced the risk of cardiovascular death and HF hospitalisation, while GLP-1RA additionally improved the functional and quality-of-life outcomes. GLP-1RA and SGLT2i significantly reduced HF morbidity, and GLP-1RA uniquely improved functional status, positioning adiposity modulation as a central therapeutic target in HFpEF.

Study context

Population
Patients with heart failure with preserved ejection fraction (HFpEF) in RCTs of pharmacotherapies (ACE inhibitors, ARBs, beta blockers, mineralocorticoid receptor antagonists (MRAs), digoxin, ARNI, SGLT2is, GLP-1 RAs, nitrates and nitrites); PubMed, Embase, Cochrane Library to April 2025
Participants
48,235 patients39 trials
Comparison
HFpEF pharmacotherapies vs placebo
Outcome
Composite of:
  • CV death
  • Heart failure (HF) hospitalisation
Methodological detailsfrequentist random-effects NMA
  • Frequentist random-effects NMA

Pooled result

As reported in the abstract

CV death and HF hospitalisation
Each group vs placeboHazard ratio (95% CI)
GLP-1 RAs
0.73(0.61–0.88)
SGLT2isP-score: 0.807
0.79(0.70–0.90)
GLP-1 RAs highest probability of ranking first (P-score)
0.871

Further pooled results

OutcomeEstimate
6MWT distanceGLP-1 RAs vs Placebomean difference +17.60 m (95% CI 8.53–26.67)
KCCQ-CSSGLP-1 RAs vs Placebomean difference +7.38 points (95% CI 5.51–9.26)
  • 6MWT distance: GLP-1 RAs elicited the greatest improvement

CV death and all-cause mortality

No statistically significant differences among the treatments

Original publication

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis. Diabetes Obes Metab. Published 26 January 2026. doi:10.1111/dom.70503

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.